algeta asa algetano founded roy h larsen Ã¸yvind bruland oslo norway private biotechnology pharmaceutical company research development focus lies field alphaparticle emitting radiopharmaceuticals lead product company xofigo first marketed alphaparticle emitting radiopharmaceutics cancer algeta raised series financing round total amount financing round led new investors healthcap advent sr march company went public traded oslo stock exchange ticker symbol algeta raised algeta lead product xofigo radium ra dichloride previously called alpharadin radiotherapeutic drug supplied injectable sterile solution active ingredient alpha particle emitting isotope mimics calcium forms complexes hydroxyapatite areas increased bone turnover takes place cancer bone metastasis product received us food drug administration fda european medicines agency approval may november respectively treat castrationresistant prostate cancer symptomatic bone metastases unknown visceral metastatic disease fda approval based doubleblind randomized placebocontrolled phase iii clinical trial patients castrationresistant prostate cancer symptomatic bone metastases trial designed measure overall survival interim analysis revealed months median overall survival xofigo group compared months placebo group data later confirmed updated exploratory analysis showing xofigo improved overall survival september algeta bayer ag anchored development commercialization deal xofigo total deal size december bayer offered full acquisition algeta largest shareholder healthcap preapproved deal completed march httpsenwikipediaorgwikialgeta